tetracycline and Nausea

Midday and evening twice-a-day quadruple therapy appears to be the most effective therapy for Helicobacter pylori infection in Northern Sardinia, a site where antibiotics resistance is common.. The objective of our study was to estimate the efficacy, side-effects, and compliance of a quadruple therapy containing esomeprazole in a group of dyspeptic elderly patients.. Consecutive elderly patients positive for H. pylori infection and not previously treated for eradication were enrolled. Therapy consisted of esomeprazole 20 mg, tetracycline 500 mg, metronidazole 500 mg, and bismuth subcitrate tablets 240 mg, all twice-a-day with the midday and evening meals, for 10 days. Efficacy was evaluated using 13C-urea breath testing. Compliance was assessed after completing treatment and at follow up. Side effects were graded based on daily activities.. Ninety-five dyspeptic patients (range 65-81 years), 52 men and 43 women, were enrolled. The intention-to-treat cure rate was 91% (81 of 89; 95% CI = 88-99%) and, 95% (81 of 85; 95% CI = 83-96%) per-protocol analysis. Compliance was excellent. Mild-moderate side effects occurred in 27 patients.. Esomeprazole containing quadruple therapy was highly successful for initial eradication of H. pylori in elderly patients.

Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Dyspepsia; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intestines; Male; Metronidazole; Nausea; Organometallic Compounds; Patient Compliance; Prospective Studies; Tetracycline

The best regimen for the treatment of Helicobacter pylori infection has yet to be defined. Four-day quadruple therapy with tetracycline, metronidazole, bismuth, and a proton pump inhibitor has been shown to obtain a very high cure rate. However, the fact that it must be taken four times daily may interfere with compliance. The objective of the study was to test the efficacy and tolerability of a new 4-day therapy with 4 drugs taken every 12 hours to cure H. pylori infection. Patients and Methods. Fifty-six consecutive patients with peptic ulcer disease and H. pylori infection were treated with an oral 4-day course with omeprazole (20 mg/12 hours), clarithromycin (500 mg/12 hours), amoxicillin (1 g/12 hours) and tinidazole (500 mg/12 hours). Efficacy of the treatment was determined at least 2 months after therapy either by biopsy (in the case of gastric ulcer) or by 13C-urea breath test. A second breath test was performed at least 6 months after therapy.. Two patients were lost to follow-up. Forty-nine of the remaining 54 patients were cured at the first control [intention-to-treat cure rate: 87.5% (CI 95% 75-94%); per protocol cure rate: 90.7% (CI 95% 81-98%)]. Forty-three of these 49 cured patients returned for a second 13C urea breath-test at 6-12 months. Two of them were not cured, giving a long-term cure rate of 85.5% per protocol and 73.2% by intention-to-treat. Compliance was good, although 25 patients had mild side effects.. This particular four-day therapy is well tolerated, easy to follow, and achieves an acceptably high cure rate.

Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diarrhea; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Nausea; Omeprazole; Organometallic Compounds; Patient Compliance; Pilot Projects; Tetracycline; Time Factors; Tinidazole; Treatment Outcome

To evaluate two triple-therapy (TT) regimens of colloidal bismuth subcitrate (CBS), metronidazole, and tetracycline HCl in eradicating Helicobacter pylori, with particular attention to the frequency of resulting adverse effects of the two therapies.. A prospective, randomized controlled trial was conducted in patients with symptoms of dyspepsia who were positive for H. pylori. Subjects received a 14-day course of either 4 x/day therapy of CBS (108 mg), tetracycline HCl (500 mg), and metronidazole (250 mg), or 5 x/day therapy of CBS (108 mg), tetracycline HCl (250 mg), and metronidazole (200 mg). H. pylori status was determined endoscopically by urease test, histology, and culture. Standard questionnaires were administered to determine compliance to treatment and side effects of therapy.. H. pylori was eradicated in 196/213 (92%) patients in the 4 x/day group and 202/210 (96%) in the 5 x/day group (p = 0.07). Side effects were significantly less frequent and less severe in the 5 x/day group (p < 0.01).. We conclude that a lower dose, 5 x/day triple therapy treatment of H. pylori is equally efficacious to the standard 4 x/day therapy, but is accompanied by fewer and milder adverse effects.

Topics: Abdominal Pain; Anti-Bacterial Agents; Constipation; Diarrhea; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Nausea; Organometallic Compounds; Patient Compliance; Prospective Studies; Tetracycline; Vomiting

The efficacy of erythromycin base (E-Mycin tablets, 333 mg) and the efficacy of tetracycline hydrochloride (Panmycin tablets) were compared in this double-blind, randomized study. Two hundred patients with moderate to moderately severe acne vulgaris were randomly assigned to the study. One hundred patients received 1 gm of erythromycin base by mouth per day for 4 weeks, followed by 333 mg/day for 8 weeks, plus placebo for tetracycline. The second group of patients received 1 gm of tetracycline by mouth per day for 4 weeks, followed by 500 mg/day for 8 weeks, plus placebo for erythromycin. Both drugs reduced acne severity to the same extent. Pustules, papules, and open comedo counts decreased significantly over the 12-week period. Seventy-seven percent of the erythromycin-treated patients and 89% of the tetracycline-treated patients stated that their acne was markedly improved or improved by week 12. Most of the side effects in patients treated with erythromycin were gastrointestinal symptoms. Among the side effects in patients treated with tetracycline were Candida vaginitis in one patient and pseudotumor cerebri in one patient.

Topics: Acne Vulgaris; Administration, Oral; Adolescent; Adult; Clinical Trials as Topic; Diarrhea; Double-Blind Method; Erythromycin; Female; Humans; Nausea; Pregnancy; Tetracycline

Topics: Adolescent; Adult; Chlorides; Clinical Trials as Topic; Female; Gonorrhea; Humans; Male; Middle Aged; Nausea; Pharyngitis; Sex Factors; Spectinomycin; Tetracycline

Topics: Abdomen; Aged; Bronchitis; Chloramphenicol; Clinical Trials as Topic; Humans; Middle Aged; Nausea; Pain; Suppuration; Tetracycline; Time Factors; Vomiting

Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Female; Humans; Male; Methacycline; Middle Aged; Naphthacenes; Nausea; Paresthesia; Photosensitivity Disorders; Placebos; Sunburn; Sunlight; Tetracycline; Time Factors; Vomiting

Topics: Clinical Trials as Topic; Diarrhea; Humans; Male; Methacycline; Nausea; Protein Binding; Tetracycline; Time Factors; Urethritis

Topics: Anti-Bacterial Agents; Clinical Trials as Topic; Diarrhea; Erythromycin; Haemophilus influenzae; Humans; Injections, Intramuscular; Intestinal Absorption; Lincomycin; Male; Mycoplasma; Nausea; Neisseria gonorrhoeae; Neisseria meningitidis; Staphylococcus; Streptococcus; Streptococcus pneumoniae; Tetracycline

The authors describe the case of a fifty-nine-year-old white man, previously in good health, who initiated his present illness with acute episode of enterocolitis characterized by mild fever and, in the next eight hours, twenty-four episodes of watery diarrhea, nausea and vomiting, as well as generalized sweating and severe weakness secondary to hypovolemia and electrolyte disorder. These complications were corrected in seventy-two hours in the intensive care unit. Two days later, when the patient was stable hemodynamically, under cardiac monitoring and with normal laboratory studies including serum electrolytes, he developed electrocardiographic changes characterized by trifascicular block (prolonged P-R interval, complete right bundle branch block [CRBBB] and left posterior hemiblock [LPH]) with a cardiac rate of thirty beats per minute, for which a temporary pacemaker was inserted. Endomyocardial biopsy showed histopathologic signs of myocarditis and the immunologic study of the cardiac tissue revealed positive polymerize chain reaction (PCR+) with the presence of antitoxine choleric antibodies (AcTCA). After three weeks, the same conduction disturbances remained, for which a permanent pacemaker was inserted. On top of intravenous fluid replacement and electrolyte supplements, the patient was managed with tetracycline 2 g a day for one week and sulfamethoxazole-trimethoprim 800/160 mg a day for two weeks. The purpose of this study is to present a rare and very well-documented myocarditis by cholera in a patient with enteric disease, in whom several cardiac complications occurred.

Topics: Anti-Bacterial Agents; Antibodies, Bacterial; Bradycardia; Bundle-Branch Block; Cholera; Diarrhea; Electrocardiography; Enterocolitis; Humans; Male; Middle Aged; Myocarditis; Nausea; Pacemaker, Artificial; Polymerase Chain Reaction; Sweating; Tetracycline; Trimethoprim, Sulfamethoxazole Drug Combination; Vibrio cholerae; Vomiting

Doxycycline is widely used to treat Lyme disease associated with erythema migrans. Whether it is comparable to tetracycline is unknown.. We conducted a two-part retrospective analysis of (1) the safety and efficacy of doxycycline compared with tetracycline and (2) the safety and efficacy of a 14-day versus a 20-day course of doxycycline.. Twenty-seven patients given tetracycline (500 mg four times a day for 14 days [group 1]) were compared retrospectively with 21 patients who received doxycycline (100 mg two or three times a day for 14 days [group 2]). The results for group 2 were also compared with that of 38 patients who received doxycycline for 20 days (100 mg three times daily) in a prospective treatment trial (group 3).. There was no significant difference in the incidence of adverse drug effects or in efficacy at 1 month, but at 1 year there was a trend toward a better outcome in the group treated with tetracycline (p = 0.08). A 14-day course of doxycycline was comparable to a 20-day course in the incidence of adverse drug effects and in clinical outcome.. The principal advantage of doxycycline over tetracycline for the treatment of Lyme disease associated with erythema migrans is the convenience of less frequent dosing, not enhanced efficacy or safety. There appears to be no advantage in extending treatment with doxycycline from 14 to 20 days.

Topics: Administration, Oral; Adult; Age Factors; Doxycycline; Drug Administration Schedule; Erythema Chronicum Migrans; Female; Follow-Up Studies; Humans; Lyme Disease; Male; Middle Aged; Nausea; Photosensitivity Disorders; Prospective Studies; Retrospective Studies; Safety; Tetracycline; Treatment Outcome

Seven cases are reported in which drugs of the tetracycline group produced a fall in the glomerular filtration rate. In six patients there was a primary underlying renal disease and renal impairment. All seven patients were made seriously ill by the antibiotic. Two patients required immediate haemodialysis; one died and the other continued on dialysis until transplanted. Another patient initially responded to intravenous fluids and protein restriction but his renal function deteriorated and four months later he began maintenance haemodialysis. Three patients required peritoneal dialysis. The seventh patient responded satisfactorily to conservative management. The medical and medicolegal complications arising from the use of tetracycline in patients with renal disease are discussed. Yet another plea is made that drugs of the tetracycline group other than doxycycline should not be given to patients with chronic renal failure.

Topics: Adult; Aged; Body Weight; Creatinine; Diarrhea; Dietary Proteins; Female; Glomerular Filtration Rate; Humans; Infusions, Parenteral; Kidney Failure, Chronic; Male; Middle Aged; Nausea; Oxytetracycline; Peritoneal Dialysis; Renal Dialysis; Tetracycline; Urea; Vomiting

Topics: Administration, Oral; Adolescent; Adult; Chlortetracycline; Demeclocycline; Diarrhea; Drug Combinations; Gonorrhea; Humans; Male; Metoclopramide; Microbial Sensitivity Tests; Nausea; Promazine; Recurrence; Tetracycline; Urethritis; Vomiting

Topics: Adolescent; Adult; Aged; Culture Media; Doxycycline; Female; Gonorrhea; Humans; Male; Middle Aged; Nausea; Penicillins; Streptomycin; Tetracycline; Vomiting

Topics: Administration, Oral; Diarrhea; Gonorrhea; Humans; Male; Nausea; New York City; Tetracycline; United States; Urethritis; Vomiting

Topics: Aged; Anti-Bacterial Agents; Chloramphenicol; Cloxacillin; Diarrhea; Enterobacteriaceae; Erythromycin; Haemophilus; Humans; Lincomycin; Nausea; Neisseria; Staphylococcus; Streptococcus; Streptococcus pneumoniae; Tetracycline

Topics: Absorption; Adult; Demeclocycline; Drug Resistance, Microbial; Feces; Humans; Male; Methacycline; Nausea; Streptococcus; Tetracycline; Urine

Topics: Actinomycosis; Adolescent; Adult; Drug Resistance, Microbial; Female; Fungi; Headache; Humans; In Vitro Techniques; Male; Middle Aged; Nausea; Phlebitis; Sclerosis; Skin Manifestations; Tetracycline; Vomiting

Topics: Adult; Ampicillin; Bacteriological Techniques; Cephalothin; Child; Chloramphenicol; Cloxacillin; Diarrhea; Eosinophilia; Erythromycin; Haemophilus influenzae; Humans; Methicillin; Nausea; Penicillin G; Penicillin G Benzathine; Penicillin G Procaine; Penicillin V; Physician-Patient Relations; Pruritus; Respiratory Tract Infections; Skin Diseases; Staphylococcus; Streptococcus; Streptococcus pneumoniae; Sulfonamides; Tetracycline; Urticaria; Vomiting

Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Bronchial Diseases; Candidiasis; Diarrhea; Lung Diseases; Nausea; Nystatin; Tetracycline; Toxicology; Vomiting